I am Akshansh Chaudhary, Executive Director and Chief Technology Officer at Venus Remedies Limited, a 35-year-old pharmaceutical company with global operations across 100+ countries. Venus is currently the largest exporter of Meropenem from India worldwide, demonstrating our leadership in carbapenem manufacturing and sterile injectable expertise. With engineering foundations from BITS Pilani Dubai and a Master's in Design & Technology from Parsons School of Design New York, I bring both technical rigor and human-centered design thinking to pharmaceutical manufacturing transformation. At Venus, I lead technology strategy, infrastructure development, plant operations, and digital transformation. We recently launched Venus Global Fulfillment Center (VGFC), integrating B2C, B2B, and export operations with end-to-end quality control. Now I'm architecting Project Venus Industrial Park (Project VIP)—a 40+ acre greenfield pharmaceutical manufacturing campus in Haryana, India, designed as a phased, multi-decade development with one new facility launching annually for 10+ years, targeting 1 billion injectable units per year capacity. Project VIP begins with piperacillin-tazobactam beta-lactam manufacturing (our first priority), followed by expanded oncology injectables facilities and continued carbapenem production excellence. Additional focus areas include cephalosporins and other sterile injectable formulations. Venus operates with established EU GMP compliance across 100+ countries. Project VIP will be designed to meet Japanese PMDA pharmacopoeia standards as we target market entry into Japan, leveraging our proven carbapenem manufacturing expertise and understanding of Asian quality philosophies. I'm at CPhi Frankfurt 2025 seeking strategic partners for Project VIP across four concrete areas: campus planning and industrial park design for 40+ acre multi-facility pharmaceutical complexes with integrated utilities and phased development capability; regulatory consulting for Japanese pharmacopoeia compliance, PMDA approval pathways, and facility design that embodies Japanese quality thinking for carbapenem and beta-lactam manufacturing; process architecture and technology selection for greenfield sterile manufacturing plants, specifically beta-lactam and carbapenem containment systems, oncology high-potency API handling, aseptic processing, and lyophilization; and Industry 4.0 integration including manufacturing execution systems, building management systems, IoT sensors, and automation approaches that amplify human capability while maintaining regulatory compliance. I'm interested in meeting equipment manufacturers for aseptic filling and packaging lines, isolator and barrier technology, lyophilization systems, sterilization equipment, and automation control systems—particularly proven GMP-compliant technologies from both European and Asian manufacturers. But beyond specifications, I want to understand: how do successful campus planners approach phased development where future needs are uncertain? What makes Japanese quality philosophy fundamentally different from Western compliance approaches, and how does that shape facility design? How do the best Industry 4.0 implementations make pharmaceutical teams more capable rather than more dependent on technology? As Executive Director and CTO, I have direct decision-making authority for technology partnerships and strategic vendor relationships. I'm looking for long-term partners who bring expertise in sterile injectable manufacturing, pharmaceutical campus development, scalable manufacturing systems, and commitment to knowledge transfer. I value partners who think about transformation holistically—understanding that the best pharmaceutical infrastructure serves both compliance requirements and human capability building. If you specialize in pharmaceutical campus master planning with phased development experience, Japanese market regulatory strategy and PMDA compliance for sterile injectables, sterile manufacturing process design for beta-lactams and carbapenems, or Industry 4.0 automation that enhances rather than replaces human judgment, I would welcome the opportunity to connect at CPhi Frankfurt 2025. Visit us at Stand No. 3.0F6 (Hall 3.0) or schedule a meeting through the CPhi portal.